A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
Status:
Active, not recruiting
Trial end date:
2022-01-05
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the safety and tolerability in participants with cold agglutinin disease (CAD),
after a single dose of intravenous (IV) BIVV020
Secondary Objectives:
To assess, in participants with cold agglutinin disease, after a single dose of intravenous
(IV) BIVV020:
- The effect of BIVV020 on complement mediated hemolysis
- The pharmacodynamics (PD) of BIVV020 relating to complement inhibition
- The pharmacokinetics (PK) of BIVV020
- The immunogenicity of BIVV020